Sanofi Acquires Dynavax for $15.50 per Share, 39% Premium
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 24 2025
0mins
Source: PRnewswire
- Acquisition Agreement: Sanofi announced its acquisition of Dynavax for $15.50 per share in cash, totaling approximately $2.2 billion, representing a 39% premium, which will enhance Sanofi's market position in adult immunization.
- Vaccine Portfolio: The acquisition includes Dynavax's marketed adult hepatitis B vaccine HEPLISAV-B and the shingles vaccine candidate (Z-1018) in development, enriching Sanofi's vaccine offerings to meet growing public health needs.
- Market Opportunity: With nearly 100 million adults in the U.S. unvaccinated against hepatitis B and shingles affecting one in three adults, the acquisition positions Sanofi to better address these unmet health needs and increase market share.
- Transaction Timeline: The deal is expected to close in Q1 2026, with Sanofi funding the acquisition through available cash resources, demonstrating its long-term commitment and strategic investment in the vaccine market.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
